NuCana
Andrew Kay is the non-executive chairman of NuCana, a biopharmaceutical company that develops novel therapies for cancer. Prior to joining NuCana, Kay served as the chairman of the board for both Wilson Therapeutics and Blueberry Therapeutics. In 2018, Wilson Therapeutics was acquired by Alexion Pharmaceuticals Inc. for $855 million. Blueberry Therapeutics was acquired by Bayer in 2020 for $875 million.
Andrew Kay completed a Bachelor of Pharmacy Honours degree at the University of Nottingham. Andrew then went on to study at Calday Grange Grammar School.
This person is not in the org chart
This person is not in any offices
NuCana
ProTide technology to transform some of the most widely prescribed chemotherapy / cancer agents